CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-11 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −3,057 | $225.00 | $688K | 21,010 |
| 2026-03-11 | Espinoza Octavio Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −2,405 | 0 | ||
| 2026-03-06 | LAMATTINA JOHN L Director | Option exercise | +2,161 | $114.15 | $247K | 32,885 |
| 2026-03-06 | LAMATTINA JOHN L Director | Sale | −2,161 | $200.76 | $434K | 30,724 |
| 2026-03-06 | LAMATTINA JOHN L Director | Option exercise · Non-Qualified Stock Option (right to buy) | −2,161 | 0 | ||
| 2026-03-04 | Reardon Andrew CLO & Secretary | Option exercise 10b5-1 | +5,000 | $52.27 | $261K | 41,869 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −100 | $197.70 | $20K | 41,769 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −100 | $199.01 | $20K | 41,669 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −207 | $199.96 | $41K | 41,462 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −93 | $200.62 | $19K | 41,369 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −300 | $201.70 | $61K | 41,069 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −200 | $204.17 | $41K | 40,869 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −460 | $205.18 | $94K | 40,409 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −340 | $206.37 | $70K | 40,069 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −612 | $207.01 | $127K | 39,457 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −1,446 | $208.12 | $301K | 38,011 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −1,142 | $208.87 | $239K | 36,869 |
| 2026-03-04 | Reardon Andrew CLO & Secretary | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −5,000 | 54,444 | ||
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Option exercise 10b5-1 | +1,607 | $58.49 | $94K | 34,619 |
| 2026-03-04 | Espinoza Octavio Chief Financial Officer | Option exercise 10b5-1 | +466 | $80.72 | $38K | 35,085 |
Page 9 of 43 · 858 trades